The stock's reaction will hinge on the ESGCT data presentation (Oct 27-30) and FDA Type C meeting minutes (October). Watch for any safety or efficacy signals in the late-breaking data that could derisk the pivotal trial design. The cash runway to mid-2027 removes near-term financing risk.
Price Chart
Executive Summary
Benitec Biopharma reported fiscal year 2026 results with a net loss of $45.5M ($0.98/share) vs $37.9M ($1.05/share) in FY2025, slightly beating consensus EPS of -$0.27 for Q3 2026. The key catalyst is the upcoming presentation of interim Phase 1b/2a BB-301 data at ESGCT in late October and anticipated FDA Type C meeting minutes, with a pivotal trial planned for mid-2027. The company is well-capitalized with $180M in cash, but the stock has historically not responded to neutral-to-bullish clinical updates (prior high-score calls underperformed).
Key Financial Metrics
Key Facts
- FY2026 net loss $45.5M vs $37.9M in FY2025; R&D spend up to $23.4M from $18.3M
- Cash and equivalents $180M as of June 30, 2026, up from $97.7M a year ago
- All 6 Cohort 1 (low-dose) BB-301 patients completed 12-month follow-up; Cohort 2 (high-dose) fully enrolled with 3 patients treated safely
- FDA Type C meeting held in Q3 2026 for pivotal study design; meeting minutes expected in October
- Interim Phase 1b/2a data accepted for late-breaking presentation at ESGCT (Oct 27-30, 2026)
- Pivotal trial initiation anticipated mid-2027
- EPS of -$0.24 for Q3 2026 beat consensus of -$0.27 by 11.1%
Financial Impact
Net loss widened 20% YoY to $45.5M; cash burn rate ~$51M/year; $180M cash provides runway into mid-2027 pivotal trial start
Risk Factors
- Phase 1b/2a data at ESGCT may not show sufficient efficacy to support pivotal trial design
- FDA Type C meeting minutes could reveal additional data requirements delaying mid-2027 pivotal start
- No revenue and widening losses; any pipeline setback would be binary for the stock
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3361525 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 20, 2026 6d ago | DEFA14A | $8.50 $8.82 | ▲ +3.76% | ▲ +4.95% | $8.59 (+1.06%) |
Oct 20, 2026 6d ago | DEF 14A | $8.50 $8.82 | ▲ +3.76% | ▲ +4.95% | $8.59 (+1.06%) |
Oct 5, 2026 21d ago | 8-K | $9.23 $9.00 | ▼ −2.49% | ▼ −3.04% | $8.59 (−6.93%) |
Sep 30, 2026 26d ago | 8-K | $9.58 $8.98 | ▼ −6.26% | ▼ −7.00% | $8.59 (−10.33%) |
Sep 22, 2026 5w ago | EFFECT | $10.95 $9.83 | ▲ +10.23% | ▲ +9.51% | $8.59 (+21.55%) |
Sep 14, 2026 6w ago | Press Release | $11.05 $11.04 | ▼ −0.09% | ▲ +0.35% | $8.59 (−22.26%) |
Jun 11, 2026 19w ago | Institutional Cluster | $11.05 $11.18 | ▲ +1.18% | ▲ +0.64% | $8.59 (−22.26%) |
Jun 11, 2026 19w ago | Institutional Cluster | $11.05 $11.18 | ▲ +1.18% | ▲ +0.64% | $8.59 (−22.26%) |
May 14, 2026 23w ago | 8-K | $11.85 $11.49 | ▼ −3.04% | ▼ −1.81% | $8.59 (−27.51%) |
May 14, 2026 23w ago | Press Release | $11.85 $11.49 | ▼ −3.04% | ▼ −1.81% | $8.59 (−27.51%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers